News

Filter

Current filters:

VivusResearch

Vivus findings show greater risk of birth defects with Qnexa ingredient

23-12-2011

USA-based drug developer Vivus (Nasdaq: VVUS) has released top-line preliminary results from its retrospective…

MetabolicsNorth AmericaPharmaceuticalQnexaRegulationResearchtopiramateVivus

Vivus obesity drug Qnexa provides substantial cardiovascular benefits

05-04-2011

USA-based Vivus (Nasdaq: VVUS), which is still struggling to get US Food and Drug Administration of its…

Cardio-vascularMetabolicsPharmaceuticalQnexaResearchVivus

Vivus leaps after releasing strong efficacy and safety data on obesity drug Qnexa

22-09-2010

USA-based Vivus (Nasdaq: VVUS) saw its shares jump 16% to $7.19 in early trading yesterday, after the…

MetabolicsPharmaceuticalQnexaResearchVivus

Positive Ph III results for VIVUS’ avanafil in diabetics with erectile dysfunction

08-06-2010

California, USA-based VIVUS announced positive results from the Phase III REVIVE-Diabetes (TA-302) study,…

avanafilDiabetesPharmaceuticalReproductiveResearchVivus

Vivus returns rights to develop Luramist to Acrux

01-04-2010

e USA’s Vivus has terminated the development and commercialization agreement with FemPharm, a wholly-owned…

AcruxLicensingLuramistPharmaceuticalReproductiveResearchVivus

Vivus stock rises as US FDA says it will review obesity drug candidate Qnexa

29-03-2010

The news that an advisory committee of the USA’s Food and Drug Adminstration is set to review California-based…

NeurologicalPharmaceuticalQnexaRegulationResearchVivus

COMPANY SPOTLIGHT

Menarini

Back to top